Genetic variation in estrogen receptor; C reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy

Moniek P.M. de Maat, Jonna Skov Madsen, Bente Langdahl, Else MArie Bladbjerg, Charlotte Landbo Tofteng, Bo Abrahamsen, Lars Rejnmark, Kim Brixen, Kaare Christensen, Jørgen Jespersen, Søren Risom Kristensen

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstrakt

    Markers of inflammation, such as C-reactive protein (CRP) and fibrinogen, are associated with the risk of atherothrombosis. Plasma levels of these markers of inflammation are affected by hormone replacement therapy (HRT) and modulated by smoking. We studied whether genetic variation in the estrogen receptor-I (ESR1), CRP and fibrinogen-β genes influences the plasma levels of inflammation markers after HRT. Plasma CRP and fibrinogen were measured after five years follow-up in healthy post-menopausal women (per-protocol group) who were randomised to hormone therapy (n=187) or no treatment (n=249). The effect of HRT, smoking and genetic variations in ESR1 (Pvull and Xbal), CRP (1444C/T) and fibrinogen-β (FGB, -455G/A) were determined. The plasma concentration of CRP was higher in the HRT group than in the control group (2.03 mg/l and 1.41 mg/l, respectively; p<0.001), while the concentration of fibrinogen was lower in the HRT group than in the control group (3.02 g/l and 3.20 g/l, respectively; p<0.001), indicating that it is unlikely that inflammation is the common underlying pathway. There was a significant interaction between smoking and HRT on the fibrinogen (p=0.02), but not on the CRP concentration (n.s.). Genetic polymorphisms in ESR1, CRP and fibrinogen were not associated with an effect of HRT on the CRP and fibrinogen plasma levels, and no significant interaction with smoking was observed. In conclusion, higher plasma levels of CRP and lower plasma levels of fibrinogen were observed in women using HRT; however, genetic polymorphisms in ESR1, CRP and FGB were not associated with these effects of HRT.

    OriginalsprogEngelsk
    Sider (fra-til)234-239
    Antal sider6
    TidsskriftThrombosis and Haemostasis
    Vol/bind97
    Udgave nummer2
    DOI
    StatusUdgivet - 1 feb. 2007

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Genetic variation in estrogen receptor; C reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy' indeholder.

    Citationsformater